Introduction to Residual Inflammation in CIDP

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a complex immune-mediated disorder affecting the peripheral nerves. Traditionally, clinicians view remission as a state of immunological silence. However, recent research indicates that CIDP remission immune activation may persist even when patients appear clinically stable. This low-grade inflammation could potentially influence long-term outcomes and treatment strategies.

A cross-sectional, case-control study recently investigated this phenomenon by examining 30 patients in remission. All participants met the 2021 EAN/PNS diagnostic criteria and were receiving maintenance intravenous immunoglobulin (IVIg). Researchers compared these patients with 30 age- and sex-matched healthy controls. Specifically, the team measured serum levels of various macrophage-related cytokines and chemokines at least one month after the last IVIg infusion.

Understanding CIDP Remission Immune Activation through Cytokines

The study results revealed significant differences between the two groups. Notably, CIDP patients in remission exhibited significantly higher levels of IL-1β, TNF-α, and IL-6 compared to healthy individuals. Furthermore, the macrophage-derived chemokines MIP-1α and MIP-1β were also elevated in the patient group. These findings suggest that the innate immune system remains active despite the absence of clinical progression or active relapses.

Moreover, researchers observed that these cytokine levels did not correlate with the Inflammatory Neuropathy Cause and Treatment (INCAT) scores. Consequently, clinical stability does not necessarily reflect a complete cessation of the underlying inflammatory process. This discrepancy highlights the importance of identifying biomarkers that can track subclinical disease activity more accurately than physical assessments alone.

Clinical Implications for Long-Term Management

Therefore, the presence of persistent macrophage-driven inflammation may have therapeutic implications. While IVIg maintenance effectively controls symptoms, it might not fully suppress the production of pro-inflammatory cytokines. Consequently, some patients might require more targeted immunomodulatory approaches to achieve true biological silence. Future studies should focus on whether these elevated markers predict eventual relapses or the progression of axonal damage over time.

Frequently Asked Questions

What does residual immune activation mean in CIDP?

It refers to persistent, low-grade inflammatory activity in the body even when a patient shows no clinical symptoms of disease progression or is considered to be in remission.

Why are macrophages important in CIDP remission?

Macrophages produce specific cytokines and chemokines, such as IL-6 and TNF-α, which drive inflammation. Their continued activity suggests that the innate immune response is still engaged despite treatment.

Can cytokine levels predict a CIDP relapse?

Current research shows elevated cytokines during remission, but more longitudinal studies are needed to determine if these specific markers can reliably predict a future clinical relapse.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Inalkac Gemici Y et al. Residual immune activation in cidp remission: the contribution of macrophage-derived cytokines and chemokines. Acta Neurol Belg. 2026 Mar 07. doi: 10.1007/s13760-026-03021-z. PMID: 41793650.

Van den Bergh PYK, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. J Peripher Nerv Syst. 2021;26(3):242-268.

Doneddu PE, et al. Validation of the 2021 EAN/PNS diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2021.